Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Iron overload is the hallmark of hereditary hemochromatosis and a complication of iron-loading anemias such as β-thalassemia. Treatment can be burdensome and have significant side effects, and new therapeutic options are needed. Iron overload in hereditary hemochromatosis and β-thalassemia intermedia is caused by hepcidin deficiency. Although transgenic hepcidin replacement in mouse models of these diseases prevents iron overload or decreases its potential toxicity, natural hepcidin is prohibitively expensive for human application and has unfavorable pharmacologic properties. Here, we report the rational design of hepcidin agonists based on the mutagenesis of hepcidin and the hepcidin-binding region of ferroportin and computer modeling of their docking. We identified specific hydrophobic/aromatic residues required for hepcidin-ferroportin binding and obtained evidence in vitro that a thiol-disulfide interaction between ferroportin C326 and the hepcidin disulfide cage may stabilize binding. Guided by this model, we showed that 7–9 N-terminal amino acids of hepcidin, including a single thiol cysteine, comprised the minimal structure that retained hepcidin activity, as shown by the induction of ferroportin degradation in reporter cells. Further modifications to increase resistance to proteolysis and oral bioavailability yielded minihepcidins that, after parenteral or oral administration to mice, lowered serum iron levels comparably to those after parenteral native hepcidin. Moreover, liver iron concentrations were lower in mice chronically treated with minihepcidins than those in mice treated with solvent alone. Minihepcidins may be useful for the treatment of iron overload disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Minihepcidins are synthetic hepcidin agonists previously shown to bind ferroportin and induce its endocytosis and proteolysis, thus preventing iron overload in hepcidin-deficient mice (Preza et al., 2011; Ramos et al., 2012).”
From Hepcidin-Induced Hypoferremia Is a Critical Host Defense Mechanism against the Siderophilic Bacterium Vibrio vulnificus (2015) · cites this paper as Preza et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other interactions between FPN and hepcidin are either hydrophobic or depend on hepcidin amide backbone atoms, which is consistent with the relatively high tolerance of amino acid substitutions within hepcidin 40 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“This led to the development of mini-hepcidin analogs containing a minimal core of 7–9 N-terminal amino acids with a single cysteine, which suffice to trigger ferroportin internalization and degradation in cells and mice (Preza et al., 2011).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Preza et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: The Hepcidin-Binding Site on Ferroportin Is Evolutionarily Conserved
De Domenico, I., Nemeth, E., Nelson, J. M., Phillips, J. D., Ajioka, R. S., Kay, M. S., Kushner, J. P., Ganz, T., Ward, D. M., & Kaplan, J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.002 · Cited by 129
Self-citationRetractedHepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Self-citationNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650
Self-citationZDOCK: An initial‐stage protein‐docking algorithm
Chen, R., Li, L., & Weng, Z. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10389 · Cited by 1,393
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
Papanikolaou, G., Samuels, M. E., Ludwig, E. H., MacDonald, M. L. E., Franchini, P. L., Dubé, M.-P., Andres, L., MacFarlane, J., Sakellaropoulos, N., Politou, M., et al. (2004) · Nature Genetics · doi:10.1038/ng1274 · Cited by 974 · cited 1×
“Discussion In hereditary hemochromatosis, hepcidin deficiency is a consequence of destructive mutations in the genes encoding hepcidin (24) or one of its regulators, HFE (3) (most common), transferrin receptor 2 (25), or hemojuvelin (26).”
BackgroundSelf-citationMutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis
Roetto, A., Papanikolaou, G., Politou, M., Alberti, F., Girelli, D., Christakis, J., Loukopoulos, D., & Camaschella, C. (2003) · Nature Genetics · doi:10.1038/ng1053 · Cited by 860 · cited 1×
“Discussion In hereditary hemochromatosis, hepcidin deficiency is a consequence of destructive mutations in the genes encoding hepcidin (24) or one of its regulators, HFE (3) (most common), transferrin receptor 2 (25), or hemojuvelin (26).”
BackgroundSreerama, N., Venyaminov, S. Y. U., & Woody, R. W. (1999) · Protein Science · doi:10.1110/ps.8.2.370 · Cited by 708
Immunoassay for human serum hepcidin
Ganz, T., Olbina, G., Girelli, D., Nemeth, E., & Westerman, M. (2008) · Blood · doi:10.1182/blood-2008-02-139915 · Cited by 688
Self-citationThe RosettaDock server for local protein-protein docking
Lyskov, S., & Gray, J. J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn216 · Cited by 592
Suppression of hepcidin during anemia requires erythropoietic activity
Pak, M., Lopez, M. A., Gabayan, V., Ganz, T., & Rivera, S. (2006) · Blood · doi:10.1182/blood-2006-06-028787 · Cited by 472 · cited 1×
“Nonheme iron concentration was determined as described (44), using”
MethodSelf-citation
Cited by
Items 101–200 of 236
Hepcidin, an overview of biochemical and clinical properties
Rauf, A., Shariati, M. A., Khalil, A. A., Bawazeer, S., Heydari, M., Plygun, S., Laishevtcev, A. I., Hussain, M. B., Alhumaydhi, F. A., & Aljohani, A. S. M. (2020) · Steroids · doi:10.1016/j.steroids.2020.108661 · Cited by 47
Yadav, P. K., & Singh, A. K. (2022) · Plasmatology · doi:10.1177/26348535221103560 · Cited by 55
“By using this mini-hepcidin, iron overload and damage to the erythroid cells are significantly reduced.(60)”
BackgroundMethodSmall cyclic agonists of iron regulatory hormone hepcidin
Chua, K. J., Fung, E., Micewicz, E. D., Ganz, T., Nemeth, E., & Ruchala, P. P. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.03.012 · Cited by 43
Self-citationYang, G., Qian, C., Zhang, C., Bao, Y., Liu, M.-Y., Jiang, F., Li, W., Liu, Y., Ke, Y., & Qian, Z. (2020) · Translational research · doi:10.1016/j.trsl.2020.09.002 · Cited by 39
Fisher, A. L., & Babitt, J. L. (2021) · Developmental Dynamics · doi:10.1002/dvdy.372 · Cited by 43
Iron as a therapeutic target in chronic liver disease
Kouroumalis, E., Tsomidis, I., & Voumvouraki, A. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i4.616 · Cited by 50
Valenti, L. V. C., Fracanzani, A. L., Rametta, R., Fraquelli, M., Soverini, G., Pelusi, S., Dongiovanni, P., Conte, D., & Fargion, S. R. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.041 · Cited by 39
“Yet, further studies are warranted to evaluate whether TMPRSS6 genotype might represent a prognostic marker to guide treatment decision and follow-up in HH, and whether manipulation of TMPRSS6 activity [31] or hepcidin analogs [46] may influence the clinical outcome.”
BackgroundRole of Iron in Aging Related Diseases
Chen, W. J., Kung, G. P., & Gnana‐Prakasam, J. P. (2022) · Antioxidants · doi:10.3390/antiox11050865 · Cited by 48
“Preclinical studies in mouse models of iron overload have shown that long acting hepcidin analogs, also referred to as minihepcidins [135,136], and antisense oligonucleotides targeting TMPRSS6, a metalloprotease that inhibits endogenous hepcidin production [137], effectively decrease iron load, improve erythropoiesis,…”
BackgroundAndrews, N. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmcibr1112780 · Cited by 43
Normal and dysregulated crosstalk between iron metabolism and erythropoiesis
Ginzburg, Y. Z., An, X., Rivella, S., & Goldfarb, A. N. (2023) · eLife · doi:10.7554/elife.90189 · Cited by 51
“binding domain (Preza et al., 2011), resulting in a significant dosedependent decrease in RBC count, hematocrit, and splenomegaly in Jak2 mice, a wellestablished mouse model of PV (Casu et al.”
BackgroundPharmacology of Iron Transport
Byrne, S. L., Krishnamurthy, D., & Wessling‐Resnick, M. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134648 · Cited by 38
Identification of Antibody and Small Molecule Antagonists of Ferroportin-Hepcidin Interaction
Ross, S. L., Biswas, K., Rottman, J., Allen, J. R., Long, J., Miranda, L. P., Winters, A., & Arvedson, T. L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00838 · Cited by 33
Prentice, A. M. (2017) · Annals of Nutrition and Metabolism · doi:10.1159/000480743 · Cited by 46
Thiol-derivatized minihepcidins retain biological activity
Fung, E., Chua, K. J., Ganz, T., Nemeth, E., & Ruchala, P. P. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.094 · Cited by 36
Self-citationControl of iron metabolism – Lessons from neonatal hemochromatosis
Zoller, H., & Knisely, A. S. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.012 · Cited by 32
“Novel therapeutic developments could therefore aim at reducing transplacental iron transport or aim at supplementing fetal hepcidin – possibly with recently developed mini-hepcidins [28].”
BackgroundRevisiting beta thalassemia intermedia: past, present, and future prospects
Salah, N. B., Bou‐Fakhredin, R., Mellouli, F., & Taher, A. T. (2017) · Hematology · doi:10.1080/10245332.2017.1333246 · Cited by 34
“Minihepcidins, or long acting hepcidin analogues,have been shown to restrict iron absorption and utilization in the setting of iron overload, with beneficial effects on ineffective erythropoiesis(74-76).”
BackgroundLiu, J., Liu, W., Liu, Y., Miao, Y., Guo, Y., Song, H., Wang, F., Zhou, H., Ganz, T., Yan, B., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.209874 · Cited by 30
Self-citationDeciphering the role of hepcidin in iron metabolism and anemia management
Kesharwani, P., Dash, D., & Koiri, R. K. (2025) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2025.127591 · Cited by 35
New strategies to target iron metabolism for the treatment of beta thalassemia
Oikonomidou, P. R., Casu, C., & Rivella, S. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13018 · Cited by 28
Şıvgın, S., & Eser, B. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1682-8 · Cited by 27
Novel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disorders
Pinto, V. M., Mazzi, F., & Franceschi, L. D. (2024) · Blood · doi:10.1182/blood.2023022193 · Cited by 33
Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy
Mast, A. E., Schlumpf, K. S., Wright, D. J., Johnson, B. R., Glynn, S. A., Busch, M. P., Olbina, G., Westerman, M., Nemeth, E., Ganz, T., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.070979 · Cited by 28
Self-citationBeta‐thalassemia and the advent of new interventions beyond transfusion and iron chelation
Chauhan, W., Shoaib, S., Fatma, R., Zaka‐ur‐Rab, Z., & Afzal, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15343 · Cited by 32
“Treated mice had reduced total iron levels in the spleen, liver and kidney coupled with decreased haemachrome and ROS formation.(138,145,146)”
BackgroundWang, C., Fang, Z., Zhu, Z., Liu, J., & Chen, H. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.05.002 · Cited by 30
Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis
Handa, S., Ginzburg, Y. Z., Hoffman, R., & Kremyanskaya, M. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000747 · Cited by 31
“Initially, preclinical studies demonstrated proofof-principle for this approach using minihepcidins, engineered peptides with the necessary functional ferroportin binding domain [64].”
BackgroundDietary iron restriction improves markers of disease severity in murine sickle cell anemia
Parrow, N. L., Violet, P.-C., George, N. A., Ali, F., Bhanvadia, S., Wong, R., Tisdale, J. F., Fitzhugh, C. D., Levine, M., Thein, S. L., et al. (2020) · Blood · doi:10.1182/blood.2020006919 · Cited by 23
Iron metabolism and chronic inflammation in IgA nephropathy
Tian, Z.-Y., Li, Z., Chu, L., Liu, Y., He, J., Yu, X., Li, A., & Zhang, H. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2195012 · Cited by 26
Ambachew, S., & Biadgo, B. (2017) · Acta Haematologica · doi:10.1159/000481391 · Cited by 27
Hepcidin as a therapeutic target in iron overload
Sandnes, M., & Reikvam, H. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2443081 · Cited by 27
“In iron-depleted, hepcidin-deficient mouse models, minihepcidins prevent liver iron accumulation, while administered in the context of preexisting iron overload, they facilitate partial redistributing of iron from parenchymal cells to macrophage stores [24,29].”
The N-terminus of hepcidin is a strong and potentially biologically relevant Cu(II) chelator
Płonka, D., & Bal, W. (2017) · Inorganica Chimica Acta · doi:10.1016/j.ica.2017.06.051 · Cited by 22
Small lipidated anti-obesity compounds derived from neuromedin U
Micewicz, E. D., Bahattab, O. S., Willars, G. B., Waring, A. J., Navab, M., Whitelegge, J. P., McBride, W. H., & Ruchala, P. P. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.020 · Cited by 24
“However in the case of retro-inverso derivatives and analog NM4A we used iminodiacetic acid mono-N-palmityl amide (Ida NHPal , see Figure 1), which we previously found to be a useful lipidation moiety [44,45].”
Self-citationRana, S., & Prabhakar, N. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.032 · Cited by 26
Song, G., Jiang, Q., Xu, T., Liu, Y., Xu, Z., & Guo, Z. (2013) · FEBS Journal · doi:10.1111/febs.12192 · Cited by 20
Guggisberg, C. A., Kim, J.-Y., Lee, J., Chen, X., & Ryu, M. (2022) · Antioxidants · doi:10.3390/antiox11101926 · Cited by 25
“To date, the most common treatment strategy for this iron disorder remains phlebotomy [2], while recent efforts for the pharmaceutical application of synthetic hepcidin analogs against iron overload have been promising [12,25].”
BackgroundLi, H., Kazmi, J. S., Lee, S. K., Zhang, D., Gao, X., Maryanovich, M., Torres, L. S., Verma, D., Kelly, L., Ginzburg, Y. Z., et al. (2022) · Blood · doi:10.1182/blood.2022016218 · Cited by 19
Wang, Y., Protchenko, O. V., Huber, K. D., Shakoury‐Elizeh, M., Ghosh, M. C., & Philpott, C. C. (2023) · Blood · doi:10.1182/blood.2023020504 · Cited by 25
Cardiac iron metabolism during aging – Role of inflammation and proteolysis
Walter, S., Mertens, C., Muckenthaler, M. U., & Ott, C. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111869 · Cited by 20
“Other hepcidin agonists in clinical trials include the small molecule VIT2763 as well as antisense oligonucleotides and siRNAs targeting TMPRSS6/matripase2 increasing endogenous hepcidin (Preza et al., 2011; Guo et al., 2013; Schmidt et al., 2013; Casu et al., 2020; Richard et al., 2020).”
Iron age: novel targets for iron overload
Casu, C., & Rivella, S. (2014) · Hematology · doi:10.1182/asheducation-2014.1.216 · Cited by 20
Actualité du métabolisme du fer
Beaumont, C., & Karim, Z. (2012) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.04.006 · Cited by 39
Biology of the iron efflux transporter, ferroportin
Rishi, G., & Subramaniam, V. N. (2020) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2020.10.005 · Cited by 22
Dekan, Z., Mobli, M., Pennington, M. W., Fung, E., Nemeth, E., & Alewood, P. F. (2014) · Angewandte Chemie · doi:10.1002/ange.201310103 · Cited by 19
Self-citationRosenblum, S. L., & Kosman, D. J. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.855751 · Cited by 21
Diaminodiacid Bridges to Improve Folding and Tune the Bioactivity of Disulfide‐Rich Peptides
Guo, Y., Sun, D., Wang, F., He, Y., Liu, L., & Tian, C. (2015) · Angewandte Chemie · doi:10.1002/ange.201500699 · Cited by 16
Cardiac injury caused by iron overload in thalassemia
Fu, C., & Yang, X. Y. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1514722 · Cited by 20
Iron as a Therapeutic Target in HFE-Related Hemochromatosis: Usual and Novel Aspects
Loréal, O., Cavey, T., Robin, F., Kenawi, M., Guggenbuhl, P., & Brissot, P. (2018) · Pharmaceuticals · doi:10.3390/ph11040131 · Cited by 18
“The development of substitutive hepcidin treatment and/or of drugs stimulating hepcidin expression is under development and could be useful to complete the therapeutic arsenal, as suggested by results obtained with mini-hepcidins [109] and BMP known to induce hepcidin expression [110].”
BackgroundIron restriction in sickle cell disease: When less is more
Castro, O. L., Franceschi, L. D., Ganz, T., Kanter, J., Kato, G. J., Pasricha, S., Rivella, S., & Wood, J. C. (2024) · American Journal of Hematology · doi:10.1002/ajh.27267 · Cited by 17
Self-citationChen, S. ‐., Yang, L. ‐., Chong, Y., Jie, Y., Wu, Y., Yang, J., Lin, G., & Li, X. (2015) · Internal Medicine Journal · doi:10.1111/imj.12764 · Cited by 17
Iron Dysregulation in Cardiovascular Diseases
Wang, H., Huang, Z., Du, C., & Dong, M. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2501016 · Cited by 19
“Therapeutic phlebotomy is an effective method for reducing iron levels, and synthetic hepcidin analogs show promise [124,125].”
BackgroundStriking the target in iron overload disorders
Finberg, K. E. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68889 · Cited by 18
“the development of small-peptide hepcidin mimetics (termed “minihepcidins”), which have shown early therapeutic promise in mouse models (6).”
Clark, R. J., Preza, G. C., Tan, C. C., van Dijk, J. W. A., Fung, E., Nemeth, E., Ganz, T., & Craik, D. J. (2013) · Biopolymers · doi:10.1002/bip.22350 · Cited by 12
Self-citationStructural basis of ferroportin inhibition by minihepcidin PR73
Wilbon, A. S., Shen, J., Ruchala, P. P., Zhou, M., & Pan, Y. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3001936 · Cited by 17
“, 2009) (Figure 1a), and mutational studies showed that the first 7 – 9 residues have a large impact on its ability to inhibit Fpn (Preza et al., 2011).”
BackgroundInfluentialSelf-citationCurrent Landscape of Hepcidin Therapeutics
Nai, A., Silvestri, L., Asperti, M., & Vinchi, F. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-92033-2_26 · Cited by 15
Wang, H., Zeng, C., Luo, G., Sun, Y., Zhang, J., Xu, Z., Guo, Y., Ye, H., Mao, J., Chen, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105698 · Cited by 14
“Previous efforts predicted the interaction between hepcidin and FPN by using molecular docking simulation and identified minihepcidin, a nonapeptide located in the N-terminus of hepcidin that exhibits an iron-regulating function.(15) Although its structure was significantly simplified, minihepcidin exhibited a signifi…”
BackgroundLuo, X. L., Jiang, Q., Song, G., Liu, Y., Xu, Z., & Guo, Z. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08695.x · Cited by 12
Novel and innovative approaches for treatment of β-thalassemia
Soni, S. (2017) · Pediatric Hematology Oncology Journal · doi:10.1016/j.phoj.2017.11.153 · Cited by 13
Tortosa, V., Bonaccorsi di Patti, M. C., Brandi, V., Musci, G., & Polticelli, F. (2017) · Bio-Algorithms and Med-Systems · doi:10.1515/bams-2017-0029 · Cited by 9
“Interestingly, in this complex hepcidin N-terminal end contacts, almost all of the residues affected by gain-of-function mutations, in agreement with the experimental evidence that the first nine residues of hepcidin are critical for hFpn binding and for the disulphide exchange process with Cys326, which triggers hFpn…”
BackgroundRole of Ferroptosis in ALD: Focusing on Hepcidin and Besides Hepcidin
Chen, L., Zhou, H., Cheng, Z., Liu, D., & Tan, Y. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673317526240924050651 · Cited by 9
An Update on Iron Homeostasis: Make New Friends, but Keep the Old
Roy, C. N. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000190 · Cited by 11
“Minihepcidins are fragments of hepcidin that are stable and retain activity against ferroportin whether given orally or parenterally.(102) They are potent hepcidin agonists, which induce hypoferremia in wild-type mice and have been used successfully to reduce iron load in hepcidin knockout mice.”
BackgroundDisorders of Iron Metabolism: Iron Deficiency and Iron Overload and Anemia of Chronic Diseases
Rivella, S., & Crielaard, B. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.07903-x · Cited by 11
Boumaiza, M., Carmona, F., Poli, M., Asperti, M., Gianoncelli, A., Bertuzzi, M., Ruzzenenti, P., Arosio, P., & Marzouki, M. N. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw066 · Cited by 9
“Hepcidin acts via its N-terminal domain of 7–9 amino acids, including a thiol cysteine, that is the minimal structure retaining hepcidin activity (Preza et al., 2011).”
BackgroundHuang, D., Bai, J., Wu, M., Wang, X., Riedl, B., Pook, E., Alt, C., Erny, M., Li, Y., Bierer, D. E., et al. (2019) · Chemical Communications · doi:10.1039/c9cc00328b · Cited by 8
Au, T. Y., Benjamin, S., & Wiśniewski, O. W. (2022) · Thalassemia Reports · doi:10.3390/thalassrep12030017 · Cited by 10
The Impact of Acute Matriptase Inhibition in Hepatic Inflammatory Models
Pomothy, J., Szombath, G., Rokonál, P., Mátis, G., Neogrády, Z., Steinmetzer, T., & Pászti-Gere, E. (2016) · BioMed Research International · doi:10.1155/2016/6306984 · Cited by 8
“Small peptide analogues containing 7–9 amino acids, minihepcidins, were successfully applied in the regulation of plasma iron concentration in mice models [23].”
MethodGonciarz, R. L., Jiang, H., Tram, L., Hugelshofer, C. L., Ekpenyong, O., Knemeyer, I. W., Aron, A. T., Chang, C. J., Flygare, J. A., Collisson, E. A., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2023.09.006 · Cited by 7
Micewicz, E. D., & Ruchala, P. P. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319100003 · Cited by 7
Self-citationMammary Leukocyte‐Assisted Nanoparticle Transport Enhances Targeted Milk Trace Mineral Delivery
Cai, J., Peng, J., Zang, X., Feng, J., Li, R., Ren, P., Zheng, B., Wang, J., Wang, J., Yan, M., et al. (2022) · Advanced Science · doi:10.1002/advs.202200841 · Cited by 6
Iron Chelation as a Potential Therapeutic Approach in Acute Lung Injury
Zhang, X., Zhou, J., Holbein, B. E., & Lehmann, C. (2023) · Life · doi:10.3390/life13081659 · Cited by 10
“Second, modulating the specific iron transporters, such as hepcidin and FPN, might provide a potential therapeutic approach [87].”
BackgroundAppropriate Clinical Genetic Testing of Hemochromatosis Type 2–4, Including Ferroportin Disease
Kowdley, D. S., & Kowdley, K. V. (2021) · The Application of Clinical Genetics · doi:10.2147/tacg.s269622 · Cited by 7
“position 326 of FPN results in minimal hepcidin internalization.(80,81) An Australian proband with cirrhosis”
BackgroundBoumaiza, M., Chahed, H., Ezzine, A., Jaouen, M., Gianoncelli, A., Longhi, G., Carmona, F., Arosio, P., Sari, M., & Marzouki, M. N. (2016) · Journal of Molecular Recognition · doi:10.1002/jmr.2561 · Cited by 7
“Hepcidin acts via its N‐terminal domain of 7 to 9 amino acids including a thiol cysteine that is the minimal structure retaining hepcidin activity.(4) The structure of hepcidin present a distorted β‐sheet shape with a hairpin loop and are stabilized by disulfide pairing of cysteine residues and hydrogen bonds between”
BackgroundIron overload due to SLC40A1 mutation of type 4 hereditary hemochromatosis
Hu, J., Li, Y., Zhang, L., Peng, G., Zhang, F., & Zhao, X. (2023) · Medical Molecular Morphology · doi:10.1007/s00795-023-00359-8 · Cited by 6
“Region F324-S343 of FPN is the suspected binding region of hepcidin [20].”
BackgroundTalha, M., Ali, M. H., Hurjkaliani, S., Rahmat, Z. S., Sadia, H., Hasibuzzaman, M. A., & Uzair, A. U. Q. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002796 · Cited by 7
“These small peptides have demonstrated efficacy in preclinical studies in mice by increasing hepcidin activity, leading to reduced iron absorption and improved iron homeostasis [25] .”
A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression
Kawabata, H., Uchiyama, T., Sakamoto, S., Kanda, J., Oishi, S., Fujii, N., Tomosugi, N., Kadowaki, N., & Takaori‐Kondo, A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.01.005 · Cited by 5
Emerging Therapies in β-Thalassemia
Bou‐Fakhredin, R., Kuo, K. H. M., & Taher, A. T. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.12.010 · Cited by 6
Sposi, N. M. (2015) · InTech eBooks · doi:10.5772/61716 · Cited by 9
“Analysis of the interface between hepcidin and ferroportin showed that the segment composed of a 9 Nterminal amino acid segment of hepcidin is sufficient for binding and internalization of ferroportin [121].”
BackgroundTertre, M. L., Ka, C., Guellec, J., Gourlaouen, I., Férec, C., Callebaut, I., & Gac, G. L. (2017) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2017.07.002 · Cited by 8
Pursuing Orally Bioavailable Hepcidin Analogues via Cyclic N-Methylated Mini-Hepcidins
Monteiro, D. G., van Dijk, J. W. A., Aliyanto, R., Fung, E., Nemeth, E., Ganz, T., Rosengren, K. J., & Clark, R. J. (2021) · Biomedicines · doi:10.3390/biomedicines9020164 · Cited by 5
“Several mini-hepcidin derivatives have been extensively characterised, with studies showing the ability of these truncated peptides to reduce iron accumulation and lower serum iron levels in hepcidin-knockout and hereditary haemochromatosis mouse models [7,12].”
BackgroundSelf-citationStructural and functional characterisation of HepTH1-5 peptide as a potential hepcidin replacement
Azemin, W.-A., Alias, N., Ali, A. M., & Shamsir, M. S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2011415 · Cited by 5
“…forms of peptide-based hepcidin that mimic hepcidin activity at systemic levels and have been used in experimental pre-clinical and clinical studies to overcome iron disorder diseases (Fung & Nemeth, 2013; Girelli et al., 2016; Preza et al., 2011; Ramos et al., 2012; Schmidt & Fleming, 2014).”
BackgroundInfluentialSerum hepcidin levels and stroke in thalassemia patients
Petrova, J. I., Manolov, V., Dimitrov, G. T., Tarnovska-Kadreva, R., Yaneva‐Sirakova, T., Velizarova, M., Vasilev, V. V., Atanasova, B. D., Tzatchev, K., Marinov, B., et al. (2016) · International Journal of Stroke · doi:10.1177/1747493015623557 · Cited by 6
“There are a few studies about microhepcidin as an alternative of chelation therapy, especially in patients without transfusion therapy.(8) Treatment with hepcidin may have a beneficial effect and ineffective erythropoiesis.”
BackgroundIn vitro reconstitution of transition metal transporters
Ongey, E. L., & Banerjee, A. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107589 · Cited by 7
“Studies conducted in mouse models JBC REVIEWS: In vitro reconstitution of transition metal transporters demonstrated that minihepcidins are promising therapeutic candidates against human diseases like b -thalassemia and he-mochromatosis (117, 118).”
BackgroundHepcidin inhibition improves iron homeostasis in ferrous sulfate and LPS treatment model in mice
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Patel, M. S., Patel, H., Savsani, H. H., & Jain, M. R. (2021) · Drug Research · doi:10.1055/a-1542-8531 · Cited by 5
“Hence, therapy is also proposed by hepcidin agonist (minihepcidin, or hepcidin derivatives such as LJPC-401) [8, 9].”
BackgroundThe C19S Substitution Enhances the Stability of Hepcidin While Conserving Its Biological Activity
Pandur, E., Fekete, Z., Tamási, K., Grama, L., Varga, E., & Sipos, K. (2018) · The Protein Journal · doi:10.1007/s10930-018-9759-9 · Cited by 4
Iron Deficiency, Iron Overload and Therapy
Crichton, R. R. (2016) · Wiley eBooks · doi:10.1002/9781118925645.ch11 · Cited by 4
Biasiotto, G., & Ferrari, F. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30246 · Cited by 4
“Moreover, mutations on hepcidin amino acids Hys3, Phe4, Ile6, Cys 7, and Phe9 are critical, and changes in this sequence determine an important loss of its functionality.(10) In covidin, these amino acids are respectively changed in Lys3, Leu4, Tyr6, Thr7 and Phe9 is missing.”
BackgroundAlfawaz, H., Alfaifi, A. A., Yakout, S. M., Khattak, M. N. K., Alnaami, A. M., Al-Thayidi, A., Elsaid, M. A., Al‐Daghri, N. M., & Alokail, M. S. (2022) · PubMed · Cited by 6
ABL-class fusion positive acute lymphoblastic leukemia: can targeting ABL cure ALL?
Tran, T. H., & Hunger, S. P. (2020) · Haematologica · doi:10.3324/haematol.2020.252916 · Cited by 3
Iron Biology: Metabolism and Homeostasis
Ganz, T. (2022) · Nutrition and health · doi:10.1007/978-3-031-14521-6_2 · Cited by 4
Self-citationIron Overload and Chelation Therapy in Hemoglobinopathies
Bou‐Fakhredin, R., Elias, J., & Taher, A. T. (2018) · Thalassemia Reports · doi:10.4081/thal.2018.7478 · Cited by 4
Hepcidin as a Molecular Hub of Iron Homeostasis: From BMP–SMAD Signaling to Therapeutic Modulation
Duminuco, A., Costa, A. N., Pilo, F., Scarso, S., Giallongo, C., Giallongo, S., Santisi, A., Sbriglione, A., Santocono, L., Caocci, G., et al. (2026) · Biomolecules · doi:10.3390/biom16070947 · Cited by 3
“Direct synthetic hepcidin analogs and minihepcidins (short peptides retaining the N-terminal pharmacophore) have shown preclinical efficacy in hemochromatosis and β -thalassemia models [135,136].”
Büyükaşık, N. Ş., & Büyükaşık, Y. (2016) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1508-107 · Cited by 4
Cocciolillo, S., Sebastiani, G., Blostein, M. D., & Pantopoulos, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00018-3 · Cited by 3
Lan, X., Ye, Z., Du, J., Liu, L., Tian, C., Huang, L., & Mo, X. (2024) · Medicine · doi:10.1097/md.0000000000038817 · Cited by 3
Hepcidin: A potent antimicrobial peptide involved in iron homeostasis
Soofiyani, S. R., Soltani, E., Nejad, M. K., Ghanbari, R., & Memar, M. Y. (2024) · Gene Reports · doi:10.1016/j.genrep.2024.102082 · Cited by 3
Skerratt, S. E., Humphreys, S., Ferreira, R., Jorgensen, C. C., Warmus, J., Zhao, L., Tong, X., & Nickolls, S. A. (2016) · MedChemComm · doi:10.1039/c6md00260a · Cited by 2
Hepcidin and the Hormonal Control of Iron Homeostasis
Frazer, D. M., & Anderson, G. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802168-2.00015-4 · Cited by 3
Brissot, P., Ropert, M., Bardou‐Jacquet, E., Latournerie, M., Jouanolle, A., & Loréal, O. (2012) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(12)71457-0 · Cited by 2
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_11 · Cited by 2
An Overlooked Hepcidin–Cadmium Connection
Płonka, D., Wiśniewska, M., Peris‐Díaz, M. D., Krężel, A., Bonna, A., & Bal, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415483 · Cited by 2
“do not have an apparent function except to potentially increase the peptide’s stability in blood [8].”
BackgroundBoumaiza, M., Poli, M., Carmona, F., Asperti, M., Gianoncelli, A., Bertuzzi, M., Arosio, P., & Marzouki, M. N. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-05234-3 · Cited by 2
Structure of human ferroportin bound to hepcidin reveals mechanisms of iron homeostasisPreprint
Billesbølle, C. B., Azumaya, C. M., Kretsch, R. C., Powers, A. S., Gonen, S., Schneider, S., Arvedson, T., Dror, R. O., Cheng, Y., & Manglik, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.16.993006 · Cited by 3
Pocket-sized iron regulators: one size fits all?
Subramaniam, V. N. (2016) · Blood · doi:10.1182/blood-2016-05-716043 · Cited by 1
“Minihepcidins, mimetics of the hepcidin peptide with improved pharmacological properties, have been reported to have therapeutic potential in animal studies for treatment of severe iron overload.(6,7) In b-thalassemia and PV, it has been postulated that iron restriction may be of therapeutic value.”
Background
Metadata
- Authors
- Preza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., Sharma, S., Waring, A., Ganz, T., & Nemeth, E.
- Affiliations
- University of California, Los Angeles (US)
- Columbia University (US)
- California Institute of Technology (US)
- University of California, Irvine (US)
- Corresponding author
- Nemeth, Elizabeta
- Venue
- Journal of Clinical Investigation
- Published
- 2011-12-01
- Volume
- 121
- Issue
- 12
- Pages
- 4880-4888
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3225996
- OpenAlex
- W2146444665
- Cited by
- 234
- References
- 45
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 11 · 2023: 15 · 2022: 18 · 2021: 12 · 2020: 16 · 2019: 15 · 2018: 12 · 2017: 29 · 2016: 18 · 2015: 20 · 2014: 13 · 2013: 22 · 2012: 17
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Funders
- National Institutes of Health
- Center for AIDS Research, University of Washington
- University of California, Irvine
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK065029, R01DK082717)
- Jonsson Comprehensive Cancer Center
- California NanoSystems Institute
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- iron overload, hereditary hemochromatosis, beta-thalassemia intermedia, ferroportin, oral bioavailability, serum iron, liver iron, peptide design
- MeSH terms
- Ferroportin, Amino Acid Sequence, Animals, Binding Sites, Computer Simulation, Cysteine, Drug Evaluation, Preclinical, Humans, Iron, Liver, Models, Molecular, Molecular Sequence Data, Peptide Fragments, Protein Conformation, Structure-Activity Relationship, Drug Design, Mutagenesis, Site-Directed, Iron Overload, Amino Acid Substitution, Antimicrobial Cationic Peptides, Protein Interaction Mapping, Cation Transport Proteins, Mice, Hydrophobic and Hydrophilic Interactions, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.